Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02230670 · ClinicalTrials.gov registry record · Phase 2
A Study of IDN-6556 in Subjects With Liver Cirrhosis
A Phase 2 study of Liver Cirrhosis and Hepatic Cirrhosis, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT02230670: Completed Phase 2 study of Liver Cirrhosis and Hepatic Cirrhosis, sponsored by Conatus Pharmaceuticals.
NCT02230670 is a Phase 2 study of Liver Cirrhosis and Hepatic Cirrhosis that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 87 participants, below the 999-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02230670, a Phase 2 study of Liver Cirrhosis and Hepatic Cirrhosis, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter study to see if treatment with IDN-6556 can help improve the liver function of patients with liver cirrhosis with Model for End-Stage Liver Disease scores between 11-18.
Primary Outcome
Baseline, Month 3, and change between for cCK18/M30
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IDN-6556
Study Locations (20)
California
- Scripps Clinic - La Jolla
- Loma Linda University Medical Center - Loma Linda
- Cedar-Sinai Medical Center - Los Angeles
- Univeristy of California, San Diego - San Diego
- California Pacific Medical Center - San Francisco
New York
- North Shore University Hospital - Manhasset
- NYU Medical Center - New York
- Mt. Sinai School of Medicine - New York
Florida
- University of Florida - Gainesville
- University of Miami - Miami
Illinois
- University of Chicago - Chicago
- Loyola University Medical Cente - Maywood
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Piedmont Atlanta Hospital - Atlanta
Indiana
- Indiana University - Indianapolis
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT02230670 record still lists
NCT02230670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 999-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Liver Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02230670 names 20 study sites across 12 states, led by California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT02230670 about?
NCT02230670 is a clinical study titled "A Study of IDN-6556 in Subjects With Liver Cirrhosis". This is a multicenter study to see if treatment with IDN-6556 can help improve the liver function of patients with liver cirrhosis with Model for End-Stage Liver Disease scores between 11-18.
What is the current status of trial NCT02230670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2014-08. Estimated completion is 2016-01.
What conditions does trial NCT02230670 study?
This clinical trial studies the following conditions: Liver Cirrhosis, Hepatic Cirrhosis.
What interventions are being tested in trial NCT02230670?
The interventions under investigation include: Placebo (DRUG), IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT02230670?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02230670 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02230670's enrollment target sits among peer trials
87 10th of 15 higher than 6 of 15 other Liver Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
RECRUITING · Phase 2
-
Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
COMPLETED · Phase 2
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia